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b-hydroxybutyrate–induced growth inhibition and collagen
production in HK-2 cells are dependent on TGF-b and Smad3.
Background. Ketonuria is common in diabetes. The major
form of ketone body is b-hydroxybutyrate (b-HB), which is me-
tabolized by the proximal tubule. Transforming growth factor b
(TGF-b) and tubulopathy are important in diabetic nephropa-
thy. Thus, the role of TGF-b and the downstream Smad3 in
b-HB–induced effects in the human proximal tubule (HK-2
cell) was studied.
Methods. Effects of b-HB (0.1 to 10 mmol/L) on HK-2 cells
were determined for: proliferation, cell cycle distribution, col-
lagen production, tubular transdifferentiation [expression of
a-smooth muscle actin (a-SMA) protein], TGF-b , Smad2/3,
p21WAF1, and p27kip1.
Results. b-HB (0.1 to 10 mmol/L) dose dependently de-
creased proliferation, arrested the cells in G0/G1 phase of the
cell cycle, and increased p21WAF1/p27kip1 protein expression at
48 hours (without affecting p21WAF1/p27kip1 mRNA and tran-
scription). b-HB (1 mmol/L) increased p21WAF1/p27kip1 protein
half-lives. b-HB (1 mmol/L) increased TGF-b transcription
at 24 hours and TGF-b1 mRNA/bioactivity at 48 hours.
b-HB (1 mmol/L) increased nuclear Smad2/3 protein ex-
pression and increased collagen production (without af-
fecting tubular transdifferentiation), which were reversed
by Smad7, dominant-negative Smad3, and N-acetylcysteine.
Dominant-negative Smad3 reversed b-HB–induced TGF-b
transcription at 24 hours, and reversed TGF-b1 bioactiv-
ity at 48 hours. Dominant-negative Smad3 reversed b-HB–
induced p21WAF1/p27kip1 protein expression at 48 hours. Finally,
N-acetylcysteine, TGF-b antibody, Smad7, and dominant-
negative Smad3 reversed b-HB (1 mmol/L)–induced growth
inhibition at 48 hours.
Conclusion. b-HB activated Smad 2/3 by oxidative stress.
TGF-b and Smad3 mediate b-HB–induced cell cycle-
dependent growth inhibition while Smad3 mediate b-HB–
induced collagen production and p21WAF1/p27kip1 protein
expression in HK-2 cells. Moreover, b-HB increased p21WAF1/
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p27kip1 protein expression by increasing p21WAF1/p27kip1 protein
stability.
Diabetic nephropathy is a major cause of end-stage re-
nal disease (ESRD) and an important cause of morbid-
ity and mortality in diabetic patients. The pathology of
diabetic nephropathy consists of glomerulopathy, tubu-
lointerstitial changes and extracellular matrix expansion
culminating in renal fibrosis [1, 2]. A partial list of the
pathogenesis of diabetic nephropathy includes glomeru-
lar hyperfiltration, renal hypertrophy, tubular transdiffer-
entiation, oxidative stress, transforming growth factor-b
(TGF-b), hyperglycemia, and dysregulation of cell cycle
proteins (e.g., p21WAF1 and p27kip1) [1, 2].
Diabetic glomerular hyperfiltration is associated with
vasoactive substances in early diabetic nephropathy
[1, 2]. For example, we have shown that renal nitric ox-
ide synthase is increased in the diabetic rats [3]. Diabetic
renal hypertrophy is cell cycle–dependent and consists of
glomerular/tubular hypertrophy [2]. We and others have
shown that TGF-b is the most important factor in diabetic
renal hypertrophy both in vitro and in vivo [2, 4]. More-
over, high glucose–induced hypertrophy and growth in-
hibition in cultured proximal tubular cells are mediated
by endogenous TGF-b [4, 5].
Many effects of TGF-b are mediated by the signal
transducer and transcription factor Smad [6]. Smads 2,
3, and 5 are receptor-associated Smads, and Smad4 is a
co-Smad, whereas Smads 6 and 7 are inhibitory Smads
[6]. Interestingly, expression of Smads 2, 3, and 4 is
increased concomitantly with TGF-b in experimental di-
abetic nephropathy [7, 8]. However, the role of Smads in
diabetic nephropathy requires validation by the specific
inhibition of Smads.
It is well known that hyperglycemia is pivotal in the
pathogenesis of diabetic nephropathy, and we and others
have extensively used high glucose–cultured renal cells
to study diabetic nephropathy [2, 4]. Additionally, tubu-
lointerstitial changes are as important as glomerulopathy
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in diabetic nephropathy, and we have been studying
the roles of renal tubules and interstitial fibroblasts
in diabetic nephropathy in vitro [2]. For example, we
have shown that high glucose inhibited proliferation in
a porcine proximal tubule-like cell line LLC-PK1 cell
[5].
Less well known is the role of ketone bodies in the
pathogenesis of diabetic nephropathy. However, sev-
eral studies have found that infusion of ketone bodies
increases glomerular filtration rate (GFR) [9–11] and
tubular proteinuria [12] with unknown mechanisms. It is
known that diabetic ketoacidosis (DKA) occurs in both
type 1 and type 2 diabetes [13]. DKA is usually diagnosed
by the presence of ketonemia and ketonuria by the ni-
troprusside test, which can only detect acetoacetate [but
not b-hydroxybutyrate (b-HB), the predominant form of
ketone body] [13]. Surprisingly, ketonuria was found in
26% of the hospitalized type 2 diabetic patients without
DKA [14]. By using the more sensitive b-HB assays, sev-
eral groups have also found that ketonemia is common
in both type 1 and type 2 diabetic patients [15–17].
Hence, human kidney 2 (HK-2) proximal tubular cells
were studied to address eight questions: First, what were
the effects of b-HB on cellular proliferation, collagen pro-
duction, and tubular transdifferentiation in HK-2 cells?
Second, what were the effects of b-HB on TGF-b bioac-
tivity and mRNA/transcriptional activity? Third, what
were the effects of b-HB on cell cycle distribution?
Fourth, what were the effects of b-HB on p21WAF1 and
p27kip1 protein expression and mRNA/transcriptional ac-
tivity? Fifth, what were the effects of b-HB on nuclear
Smad2/3 protein expression? Sixth, was b-HB–induced
growth inhibition mediated by TGF-b? Seventh, were
b-HB–induced Smad 2/3, collagen production and
growth inhibition mediated by oxidative stress? Finally,
were b-HB–induced TGF-b , p21WAF1, p27kip1, collagen
production, and growth inhibition mediated by Smad3?
METHODS
Cells and reagents
HK-2 cells (CRL-2190) were obtained from the
American Type Culture Collection (ATCC, Rockville,
MD, USA). According to a previous study [18], cells
were grown to confluence in culture flasks in Dulbecco’s
modified Eagle’s medium (DMEM)/F12 medium
(11 mmol/L dextrose) and supplemented with 5% fetal
calf serum (FCS), 100 U/mL penicillin, 100 lg/mL strep-
tomycin, 2 mmol/L L-glutamine, 5 lg/mL insulin, 5 lg/mL
transferrin, 5 ng/mL sodium selenite, 5 pg/mL T3, 5 ng/mL
hydocortisone, 5 pg/mL prostaglandin E1 (PGE1), and
10 ng/mL epidermal growth factor. Cells were plated on
plastic culture flasks and fed by changing the medium
every other day. We used the trypan blue exclusion test
to assess cell viability, which was regularly over 92%.
Cells were seeded in culture plates for 24 hours, and
fasted (0.5% FCS and 11 mmol/L glucose) for another
24 hours. After the medium was aspirated, cells were
treated with 11 mmol/L glucose (control) or sodium
D-(-)-b-HB (0.1 to 10 mmol/L in 11 mmol/L glucose)
(Sigma-Aldrich Co., St. Louis, MO, USA) in 5% FCS-
containing medium for another 24 or 48 hours. Some cells
were pretreated with pan-specific rabbit-anti-TGF-b
neutralizing antibody (R&D Systems, Minneapolis,
MN, USA) for 1 hour before treating with b-HB,
while nonimmune rabbit IgG was used as a control.
Antibodies against Smad2/3, p21WAF1, and p27kip1 were
obtained from Santa Cruz Biotechnologies (Santa Cruz,
CA, USA). All other reagents were obtained from
Sigma-Aldrich Co. (St. Louis, MO, USA).
Plasmids
The human TGF-b1 promoter-luciferase construct,
phTG5-Luc, was kindly provided by Dr. Virelizier [19].
The human p27kip1 promoter-luciferase construct, p27PF,
was kindly provided by Dr. Sakai [20]. The human
p21WAF1 promoter-luciferase construct, WWP-Luc, was
kindly provided by Dr. Vogelstein [21]. The Smad7
expression plasmid was kindly provided by Dr. ten
Dijke [22]. The dominant-negative pcDNA3Smad3C
was kindly provided by Dr. Derynck [23].
Cellular proliferation
Cells were plated at a density of 4 × 104/well in 24-well
plates. Cellular proliferation was studied by cell numbers
and [3H]-thymidine incorporation into DNA as described
previously [24]. Briefly, cells were manipulated as de-
scribed in the first section. During the last 4 hours of cul-
ture, cells were pulsed with 2 lCi/mL of [3H]-thymidine.
Radioactivities were counted in a liquid scintillation b
counter. Cell number was counted with a hemocytome-
ter. Cytotoxicity was determined by trypan blue exclusion
and lactate dehydrogenase release tests.
Cell cycle analysis
This was performed by flow cytometry using the Cycle
TestTM Plus DNA Reagent Kit (Becton-Dickinson and
Co., Mountain View, CA, USA) as described previously
[25]. Briefly, 106 cells were subjected to trypsin and ri-
bonuclease A treatment, stained by propidium iodide and
analyzed by using the FACscan flow cytometer (Becton-
Dickinson and Co., Paramus, NJ, USA). The percentage
of cells in the G0/G1, S and G2/M phase of cell cycle were
determined by computer analysis.
TGF-b bioassay
Mink lung epithelial cells (CCL-64) (ATCC) were used
to test the bioactivity of TGF-b expressed by HK-2 cells
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as described previously [25]. Briefly, an aliquot of the
cultured supernatant from HK-2 cells was assayed for
TGF-b bioactivity (active fraction). Another aliquot of
supernatant was subjected to heat activation at 80◦C for
15 minutes (total fraction). The ability of the HK-2 cul-
tured supernatant to inhibit [3H]-thymidine incorpora-
tion of mink lung cells attributed to TGF-b activity was
examined by pretreatment with 20 ng/mL pan-specific
neutralizing antibody (R&D Systems), which reversed
the growth-inhibitory effect of 1 ng/mL TGF-b1 by 80%.
Real-time reverse transcription-polymerase
chain reaction (RT-PCR)
Quantization of TGF-b1, p21WAF1, and p27kip1 mRNA
was performed by fluorogenic 5′ nuclease assay-based
TaqMan real-time RT-PCR by using the ABI PRISM
7900 Sequence Detection System (Perkin-Elmer, Inc.,
Boston, MA, USA). Briefly, total RNA was extracted
as described in our previous study [25], and primers
and probes were purchased (ABI Assays-on-Demand
Gene Expression Products, TGF-b1: Hs00171257 ml,
p21WAF1: Hs00355782 ml, p27kip1: Hs00153277 m1)
(Perkin-Elmer, Inc.). The probes contain a fluorescent
reporter (6-carboxyfluorescein) at the 5′ end and a
nonfluorescent quencher at the 3′ end. After RT, 1
lg of total RNA was used to generate cDNA using a
random primer. Equal amounts of cDNA were used in
triplicate and amplified with the TaqMan Master Mix.
Products were quantified by using the relative standard
curve method and expressed as the ratio between each
mRNA and glyceraldehyde-3-phosphate-dehydrogenase
(GAPDH). Moreover, the relative unit of 0 mmol/L
b-HB was assumed to be 1.0.
Transient transfection and luciferase assay
Cells were plated onto 6-well plates at a density of
105 cells/well and grown overnight. Cells were trans-
fected with 2 lg of phTG5-Luc, WWP-Luc, p27PF, 1 lg
of Smad7, pcDNA3Smad3C, or the empty vector with
LipofectAMINE method as described previously [26].
Cells were also transfected with 1 lg of CMV-SPORT-b-
galactosidase (Gibco-BRL, Rockville, MD, USA) to con-
trol for transfection efficiency. Cells were then incubated
with b-HB (1 mmol/L) for 24 hours, and the luciferase/
b-galactosidase activity ratio was calculated. The results
were shown as an average of three independent experi-
ments of triplicate samples.
Preparation of nuclear extracts
Because activated Smad 2/3 is followed by nuclear
translocation [6], this procedure was performed as previ-
ously described [27] to prepare nuclear proteins (contain-
ing transcription factors) for immunoblotting Smad 2/3.
Briefly, after various treatments, cells were harvested and
vigorously vortexed. Next, cell lysates were centrifuged,
and nuclear pellets were resuspended in nuclear extrac-
tion buffer. Nuclear proteins were measured for protein
by using a Bio-Rad Protein Assay Kit. Extracts were
stored at –70◦C for further use.
Immunoblotting
Immunoblotting was performed as described previ-
ously [27]. Briefly, total cell lysates were resolved by 10%
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE), transferred to membranes and blocked,
and then probed with Smad2/3, p21WAF1, or p27kip1 anti-
bodies. The membranes were washed and reprobed with
actin antibody to control for protein loading. The bands
were detected using the enhanced chemiluminescence
system and quantitated using a scanning densitometer.
Relative densities were shown as the ratio between the
specific proteins and actin. Moreover, the relative density
of 0 mmol/L b-HB or time 0 was assumed to be 1.0.
Assay for p21WAF1 and p27kip1 protein stability
According to a previous study [28], assay for protein
stability was performed by serial immunoblotting of pro-
tein after new protein synthesis was inhibited by 20 lg/mL
cycloheximide. Briefly, cells was treated with cyclohex-
imide and p21WAF1 and p27kip1 protein expression was
followed for 3 hours. Whole cell lysates were prepared
at indicated times and subjected to immunoblotting. The
bands were quantified and the protein half-life was cal-
culated from the slope of the best-fit line.
Statistics
The results were expressed as the mean ± standard
errors of the mean (SEM). One-way analysis of vari-
ance (ANOVA) was performed for the global compar-
ison among three or more groups. Afterwards, post hoc
tests were performed by the Dunnett test, which com-
pares a control to the other groups. A P value of less than
0.05 was considered as statistically significant.
RESULTS
Cellular proliferation
Cellular proliferation, measured by [3H]-thymidine in-
corporation and cell number, was performed in HK-2
cells after timed exposure to b-HB at various doses. Thus,
b-HB (0.1 to 10 mmol/L) had no effects on cellular pro-
liferation at 24 hours (data not shown). In contrast, as
shown in Figure 1, b-HB (0.1 to 10 mmol/L) dose depen-
dently decreased cellular proliferation in HK-2 cells at
48 hours. TGF-b1 [0.62 ng/mL, the same concentration
as b-HB (1 mmol/L)–induced TGF-b bioactivity] also
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B Fig. 1. Effects of b -hydroxybutyrate (b -
HB) (striped bars) and transforming growth
factor-b1 (TGF-b 1) (stippled bar) on [3H]-
thymidine incorporation (A) and cell num-
bers (B) in human kidney 2 (HK-2) cells at
48 hours. b-HB (0.1 to 10 mmol/L) dose
dependently decreased cellular proliferation
while TGF-b1 (0.62 ng/mL) also decreased
cellular proliferation. The results are shown as
the mean of three independent experiments
performed in triplicate. Post hoc tests were
performed by the Dunnett test, which com-
pares 0 mmol/L b-HB to the other groups.
∗P < 0.05 vs. 0 mmol/L b-HB.
Table 1. Effects of b-hydroxybutyrate (b-HB) (1 mmol/L) treatment
for 48 hours on cell cycle distribution in human kidney 2 (HK-2 cells)
G0/G1 S G2/M
b-HB (0 mmol/L) 48.6% ± 1.2% 29.1% ± 2.1% 22.3% ± 0.4%
b-HB (1 mmol/L) 68.3% ± 1.6%a 19.6% ± 1.6% 12.1% ± 0.8%
Results are expressed as the mean ± SEM of three independent experiments.
aP < 0.05 vs. 0 mmol/L b-HB.
decreased cellular proliferation at 48 hours. b-HB did not
induce cytotoxicity as determined by trypan blue exclu-
sion or lactate dehydrogenase release (data not shown).
Thus, b-HB decreased proliferation of HK-2 cells by a
mechanism independent of cytotoxicity.
Cell cycle analysis
Cell cycle–dependent growth is a probable way of
cytotoxicity-independent growth regulation. Thus, cell
cycle analysis was performed by flow cytometry. As shown
in Table 1, b-HB (1 mmol/L) increased the percentage of
cells arrested in the G0/G1 phase. Thus, inhibition of cel-
lular proliferation by b-HB was associated with an arrest
of the cells in the G0/G1 phase of the cell cycles in the
HK-2 cells.
Collagen production and tubular transdifferentiation
Overproduction of extracellular matrix is pivotal in di-
abetic renal fibrosis [2]. Thus, collagen production was
assessed by [3H]-proline incorporation. As shown in
Figure 2, b-HB dose dependently (0.1 to 10 mmol/L) in-
creased medium-released (but not cell-associated) colla-
gen at 48 hours. Moreover, N-acetylcysteine (10 mmol/L),
Smad7, and dominant-negative Smad3 plasmids re-
versed b-HB (1 mmol/L)–induced collagen production at
48 hours. Additionally, tubular epithelial-myofibroblast
transdifferentiation is pivotal in diabetic nephropathy [1].
Thus, tubular transdifferentiation was assessed by im-
munoblotting a-smooth muscle actin (a-SMA) in HK-2
cells after timed exposure to b-HB or TGF-b1. As shown
in Figure 3, b-HB (1 mmol/L) and TGF-b1 (0.62 ng/mL)
failed to increase a-SMA at 48 hours. However, TGF-
b1 (10 ng/mL) increased a-SMA protein expression at
48 hours. Thus, b-HB (1 mmol/L) did not induce tubular
transdifferentiation in HK-2 cells.
TGF-b bioactivity, TGF-b1 mRNA, and TGF-b
transcriptional activity
We and others have shown that TGF-b is an important
regulator of cell cycle–dependent growth in renal tubu-
lar cells [4, 5]. Thus, TGF-b bioactivity was assessed by
the ability of conditioned medium to inhibit Mink lung
epithelial cell proliferation. TGF-b1 mRNA was quan-
tified by real-time PCR while TGF-b transcriptional ac-
tivity was assessed by the ability of conditioned medium
to activate the TGF-b promoter construct. As shown in
Table 2, b-HB (1 mmol/L) increased TGF-b bioactivity
at 48 hours. Moreover, b-HB dose dependently (0.1 to
10 mmol/L) increased TGF-b transcriptional activity at
24 hours (Fig. 4A) and TGF-b1 mRNA expression at
48 hours (Fig. 4B). Thus, b-HB increased TGF-b bioac-
tivity by increasing TGF-b transcriptional activity and
TGF-b mRNA expression.
Effects of b-HB on p21WAF1, and p27kip1 mRNA/protein
expression and promoter activity
Because b-HB–induced growth inhibition in HK-2
cells was cell cycle–dependent while p21WAF1 and
p27kip1 are important in cell cycle regulation in dia-
betic nephropathy [2], we assessed p21WAF1 and p27kip1
mRNA/protein expression and p21WAF1/p27kip1 pro-
moter activity after timed exposure to b-HB at various
doses. Thus, as shown in Figure 5, b-HB dose dependently
(0.1 to 10 mmol/L) increased p21WAF1 and p27kip1 protein
expression at 48 hours. In contrast, b-HB (1 mmol/L) did
not affect transcriptional activities at 24 hours (Fig. 6A)
and p21WAF1 and p27kip1 mRNA expression at 48 hours
(Fig. 6B). Note that b-HB (1 mmol/L) also did not af-
fect p21WAF1 and p27kip1 mRNA and transcriptional ac-
tivities at 4 to 24 hours (data not shown). In contrast,
b-HB (1 mmol/L) increased p21WAF1 protein half-life
(from 11/2 hours to 21/2 hours) and p27kip1 protein half-
life (from 3 hours to 4 hours) as demonstrated by serially
immunoblotting p21WAF1 and p27kip1 protein after treat-
ment with cycloheximide.
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Fig. 2. Dose-dependent effect of b -
hydroxybutyrate (b -HB) on collagen
production in human kidney 2 (HK-2)
cells at 48 hours. Collagen production was
assessed by [3H]-proline incorporation.
Cells were transfected with Smad7 or
pcDNA3Smad3C as described in the Meth-
ods section. CMV-SPORT-b-galactosidase
was used to control for transfection efficiency.
b-HB dose dependently (0.1 to 10 mmol/L)
increased medium-released collagen (A) but
not cell-associated collagen (B). Moreover,
N-acetylcysteine (10 mmol/L, fifth bar),
pcDNA3Smad3C (sixth bar), and Smad7
(seventh bar) reversed b-HB (1 mmol/L)–
induced medium-released collagen produc-
tion (A). The results are shown as an average
of three independent experiments performed
in triplicate. Post hoc tests were performed by
the Dunnett test, which compares 1 mmol/L
b-HB alone to the other groups. ∗P < 0.05 vs.
1 mmol/L b-HB alone.
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Fig. 3. Effect of b -hydroxybutyrate (b -HB) and transforming growth
factor-b1 (TGF-b1) on a -smooth muscle actin (a -SMA) (upper panel)
protein expression. Medium alone (lane 1), 0.62 ng/mL TGF-b1 (lane
2), 10 ng/mL TGF-b1 (lane 3), and 1 mmol/L b-HB (lane 4) was added
to human kidney 2 (HK-2) cells for 48 hours. Actin (lower panel) was
reprobed to control for protein loading. Total cell lysates were im-
munoblotted with a-SMA antibodies as described in the Methods sec-
tion. It is evident that TGF-b1 (10 ng/mL) increased a-SMA protein
expression. However, TGF-b1 (0.62 ng/mL) and b-HB (1 mmol/L) did
not affect a-SMA protein expression. The results are shown as an aver-
age of three independent experiments. Post hoc tests were performed
by the Dunnett test, which compares lane 1 to the other lanes. ∗P < 0.05
versus lane 1.
Time-dependent effects of b-HB on nuclear Smad2/3
protein expression
Because Smad2/3 is a downstream mediator of TGF-
b , while TGF-b activates Smad2/3 by phosphorylation
followed by nuclear translocation [6], nuclear Smad2/3
Table 2. Effects of b-hydroxybutyrate (b-HB) (1 mmol/L) or
dominant-negative Smad3 (pcDNA3Smad3C) treatment for
48 hours on transforming growth factor-b (TGF-b) bioactivity in
human kidney 2 (HK-2) cells
Active Total
fraction fraction
Plasmid ng/mL ng/mL
b-HB (0 mmol/L) — 0.28 ± 0.04a 0.65 ± 0.08
b-HB (1 mmol/L) — 0.62 ± 0.06 0.8 ± 0.1
b-HB (1 mmol/L) pcDNA3Smad3C 0.36 ± 0.05a 0.54 ± 0.12
b-HB (1 mmol/L) Empty vector 0.66 ± 0.15 0.82 ± 0.18
Results are expressed as the mean ± SEM of three independent experiments
performed in triplicate. Post hoc tests were performed by the Dunnett test, which
compares the empty vector to the other groups.
aP < 0.05 vs. empty vector.
was assayed by immunoblotting nuclear extract of HK-2
cells treated by b-HB for 2 to 24 hours. Thus, as shown in
Figure 7, nuclear Smad2/3 protein expression was time
dependently increased by b-HB (1 mmol/L) at 2 to
8 hours and then fell at 8 to 24 hours. Moreover,
N-acetylcysteine reversed b-HB (1 mmol/L)–induced nu-
clear Smad2/3 protein expression.
Neutralizing TGF-b antibody, Smad7,
dominant-negative Smad3, and N-acetylcysteine
reversed growth-inhibitory effects of b -HB
The role of TGF-b , Smads, and oxidative stress in
b-HB–induced growth inhibition was assessed by neu-
tralizing TGF-b antibody, transient transfection of the
Smad7, and dominant-negative Smad3 plasmids and
N-acetylcysteine. Cells were pretreated with neutraliz-
ing TGF-b antibody (20 ng/mL) for 1 hour before adding
b-HB. As shown in Figure 8, TGF-b antibody, Smad7,
dominant-negative Smad3, or N-acetylcysteine reversed
b-HB (1 mmol/L)–induced growth inhibition in HK-2
cells at 48 hours. However, nonimmune IgG or empty
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Fig. 4. Dose-dependent effects of b -
hydroxybutyrate (b -HB) on transforming
growth factor-b (TGF-b) promoter (phTG5-
Luc) activity and TGF-b1 mRNA expression
in human kidney 2 (HK-2) cells at 24 hours.
For the assessment of TGF-b transcriptional
activity, cells were transfected with phTG5-
Luc as described in the Methods section.
CMV-SPORT-b-galactosidase was used to
control for transfection efficiency. TGF-b1
mRNA was quantified by real-time reverse
transcription-polymerase chain reaction (RT-
PCR) and expressed as the ratio between
TGF-b1 and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA. (A)
b-HB (0.1 to 10 mmol/L) dose dependently
increased TGF-b transcriptional activity at
24 hours. (B) b-HB (0.1 to 10 mmol/L) dose
dependently increased TGF-b1 mRNA at
48 hours. The results are shown as an average
of three independent experiments. Post hoc
tests were performed by the Dunnett test,
which compares 0 mmol/L b-HB to the other
groups. ∗P < 0.05 vs. 0 mmol/L b-HB. ∗∗P <
0.01 vs. 0 mmol/L b-HB.
0 0.1 1 10
0.0
0.5
1.0
1.5
2.0
2.5
3.0 *
*
β-HB, mmol/L
β-HB, mmol/L
R
el
at
iv
e 
de
ns
ity
0 0.1 1 100.0
0.5
1.0
1.5
2.0
2.5
*
*
R
el
at
iv
e 
de
ns
ity
Fig. 5. Dose-dependent effects of b-hydroxybutyrate (b-HB) on
p21WAF1 (upper panel) or p27kip1 (middle panel) protein expression
in human kidney 2 (HK-2) cells at 48 hours. Actin (lower panel) was
reprobed to control for loading. Total cell lysates were immunoblot-
ted with p21WAF1 or p27kip1 antibodies as described in the Methods
section. It is evident that p21WAF1 was dose dependently increased by
b-HB (0.1 to 10 mmol/L), whereas p27kip1 was dose dependently in-
creased by b-HB (0.1 to 1 mmol/L) until it reached a plateau at a b-HB
concentration of 1 to 10 mmol/L. Relative densities are shown as an av-
erage of three independent experiments. Post hoc tests were performed
by the Dunnett test, which compares 0 mmol/L b-HB alone to the other
groups. ∗P < 0.05 vs. 0 mmol/L b-HB.
vectors did not affect b-HB (1 mmol/L)–induced growth
inhibition in these cells (data not shown).
Dominant-negative Smad3 reversed b -HB–induced
TGF-b promoter activity and bioactivity
The role of Smad3 in b-HB–induced TGF-b transcrip-
tional activity and bioactivity was assessed by transient
transfection of the dominant-negative Smad3 plasmid.
Thus, dominant-negative Smad3, but not the empty
vector, reversed b-HB (1 mmol/L)–induced TGF-b tran-
scriptional activity at 24 hours (Fig. 9) and TGF-b bioac-
tivity at 48 hours (Table 2).
Effects of dominant-negative Smad3 on b -HB–induced
p21WAF1 or p27kip1 protein expression
and promoter activities
The role of Smad3 in b-HB–induced p21WAF1 or
p27kip1 protein expression and transcriptional activity
was assessed by transient transfection of the Smad7 or
dominant-negative Smad3 plasmid. Thus, as shown in
Figure 10, dominant-negative Smad3, but not the empty
vector, reversed b-HB (1 mmol/L)–induced p21WAF1
and p27kip1 protein expression at 48 hours. However,
dominant-negative Smad3 did not affect p21WAF1 and
p27kip1 transcriptional activities at 24 hours (Fig. 6).
DISCUSSION
This is the first demonstration of the effects of b-HB
on renal cells in terms of cellular growth and collagen
production. Thus, we showed that b-HB inhibited cel-
lular proliferation and increased collagen production in
renal tubular cells (i.e., HK-2 cells). In contrast, there
have been only two previous studies on the effects of
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Fig. 6. Effects of b -hydroxybutyrate
(b-HB) and dominant-negative Smad3
(pcDNA3Smad3∆C) plasmid on p21WAF1
() or p27kip1 ( ) promoter activity at
24 hours and mRNA at 48 hours in hu-
man kidney 2 (HK-2) cells. Cells were
transfected with WWP-Luc, p27PF, or
pcDNA3Smad3C as described in the Meth-
ods section. CMV-SPORT-b-galactosidase
was used to control for transfection efficiency.
P21WAF1 or p27kip1 mRNA was quantified by
real-time reverse transcription-polymerase
chain reaction (RT-PCR) and expressed as
the ratio between p21WAF1 or p27kip1 and
glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA. (A) b-HB (1 mmol/L)
or dominant-negative Smad3 did not affect
p21WAF1 or p27kip1 transcriptional activities.
(B) b-HB (1 to 10 mmol/L) did not affect
p21WAF1 or p27kip1 mRNA expression. The
results are shown as an average of three
independent experiments. Post hoc tests
were performed by the Dunnett test, which
compares 0 mmol/L b-HB to the other
groups.
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Fig. 7. Time-dependent effects of 1 mmol/L
b -hydroxybutyrate (b -HB) (upper panel) on
nuclear Smad2/3 protein expression in human
kidney 2 (HK-2) cells. Actin (lower panel)
was reprobed to control for loading. Nuclear
extracts were immunoblotted with Smad2/3
antibodies as described in the Methods sec-
tion. b-HB (1 mmol/L) time dependently
(2 to 8 hours) increased Smad2/3 protein
expressions and then fell at 8 to 24 hours.
Moreover, N-acetylcysteine (10 mmol/L)
(rightmost bar) reversed b-HB (1mmol/L)–
induced Smad2/3 nuclear translocation. Rela-
tive densities are shown as an average of three
independent experiments. Post hoc tests were
performed by the Dunnett test, which com-
pares 0 hour to the other groups. ∗P < 0.05 vs.
0 hour; ∗∗P < 0.01 vs. 0 hour.
ketone bodies in cultured renal cells in terms of cel-
lular metabolism. These two studies found that b-HB
(0.5-5 mmol/L) activates gluconeogenesis and/or inhibits
ammoniagenesis in cortical renal tubules [29, 30].
Serum levels of ketone bodies are normally less than
0.1 mmol/L while they may reach 0.35 mmol/L in type 2
diabetic patients, 1.05 to 3.2 mmol/L in poorly controlled
diabetic patients and 3-12.3 mmol/L in DKA, respectively
[31–35]. Because the concentration of b-HB in the early
proximal tubule equals that in plasma [36], we used b-HB
in the range of 0.1 ∼ 10 mmol/L to encompass the ranges
achievable in diabetic and DKA patients. Moreover, be-
cause hyperketonemia can be defined as levels in excess
of 1 mmol/L [32–35], we used 1 mmol/L b-HB in all of
the studies except the initial dose-finding studies.
In a previous study, we found that high glucose-induced
growth effects in distal tubule-like Madin-Darby canine
kidney (MDCK) cells were cell cycle–dependent [25]. In
this study, we found that b-HB–inhibited cellular prolif-
eration was associated with an arrest of the cells in the
G0/G1 phase in HK-2 cells. Interestingly, it is known that
an arrest of the cells in the G0/G1 phase is associated with
growth inhibition and cellular hypertrophy [2].
Diabetic nephropathy has been linked to p21WAF1
and p27kip1 [2], two of the downstream targets of TGF-
b [37]. We and others have shown that p21WAF1 and
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Fig. 8. Effects of neutralizing trans-
forming growth factor-b (TGF-b) an-
tibody, Smad7, and dominant-negative
Smad3 (pcDNA3Smad3∆C) plasmids
or N-acetylcysteine (10 mmol/L) on
b -hydroxybutyrate (b-HB) (1 mmol/L)–
inhibited mitogenesis in human kidney 2
(HK-2) cells at 48 hours. TGF-b antibody,
Smad7, dominant-negative Smad3, or
N-acetylcysteine reversed b-HB (1 mmol/L)-
inhibited mitogenesis. The results are
shown as an average of three independent
experiments performed in triplicate. Post hoc
tests were performed by the Dunnett test,
which compares 0 mmol/L b-HB to the other
groups. ∗P < 0.05 vs. 0 mmol/L b-HB.
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Fig. 9. Effects of dominant-negative
Smad3 (pcDNA3Smad3∆C) plasmid on
b -hydroxybutyrate (b-HB) (1 mmol/L)–
induced transforming growth factor-b
(TGF-b) promoter (phTG5-Luc) activity
in human kidney 2 (HK-2) cells. Cells
were transfected with phTG5-Luc or
pcDNA3Smad3C as described in the Meth-
ods section. CMV-SPORT-b-galactosidase
was used to control for transfection efficiency.
Dominant-negative Smad3 (but not the
empty vector) reversed b-HB (1 mmol/L)–
induced TGF-b transcriptional activity at 24
hours. The results are shown as an average
of three independent experiments. Post hoc
tests were performed by the Dunnett test,
which compares 0 mmol/L b-HB to the other
groups. ∗∗P < 0.01 vs. 0 mmol/L b-HB.
p27kip1 are associated with growth arrest in transformed
and nontransformed cells [2, 38, 39]. In this study,
we showed that b-HB enhanced TGF-b transcriptional
activity/bioactivity, and p21WAF1 and p27kip1 protein ex-
pression in HK-2 cells. Moreover, b-HB–induced growth
inhibition was reversed by neutralizing TGF-b antibody.
In view of a recent study showing that TGF-b–inhibited
renal tubular proliferation is dependent on p21WAF1 and
p27kip1 [40], b-HB–induced growth inhibition is likely de-
pendent on TGF-b–induced p21WAF1 and p27kip1 protein
expression in HK-2 cells.
In the present study, we found that b-HB in-
creased p21WAF1 and p27kip1 protein expression with-
out affecting their mRNA/transcriptional activities.
Additionally, dominant-negative Smad3 also did not af-
fect p21WAF1 and p27kip1 transcriptional activities. These
observations are compatible with the finding that the pro-
moters of p21WAF1 and p27kip1 do not contain the Smad-
binding elements [20, 37]. In fact, p21WAF1 and p27kip1 can
be regulated by either transcriptional or posttranscrip-
tional mechanisms [2, 38, 39, 41]. An important mech-
anism of posttranscriptional regulation of p21WAF1 and
p27kip1 is through protein kinase–dependent phosphory-
lation [41]. Phosphorylated p21WAF1 and p27kip1 are then
degraded by ubiquitination [41]. To delineate the role of
this important posttranscriptional regulation of p21WAF1
and p27kip1, we determine their protein stabilities and
found that b-HB (1 mmol/L) increased p21WAF1 and
p27kip1 protein half-lives. Thus, b-HB induced p21WAF1
and p27kip1 protein expression by increasing p21WAF1 and
p27kip1 protein stabilities in HK-2 cells.
Overproduction of extracellular matrix and tubular
myofibroblast transdifferentiation are two of the im-
portant mechanisms of diabetic renal fibrosis [1, 2]. In
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Fig. 10. Effects of dominant-negative
Smad3 (pcDNA3Smad3∆C) plasmid on
b-hydroxybutyrate (b-HB) (1 mmol/L)–
induced p21WAF1 (upper panel) or p27kip1
(middle panel) protein expression in HK-2
cells. Actin (lower panel) was reprobed to
control for loading. Total cell lysates were
immunoblotted with p21WAF1 or p27kip1
antibodies as described in the Methods
section. Dominant-negative Smad3 (but
not the empty vector) reversed b-HB
(1 mmol/L)–induced p21WAF1 and p27kip1
protein expressions at 48 hours. Relative
densities are shown as an average of three
independent experiments. Post hoc tests
were performed by the Dunnett test, which
compares 0 mmol/L b-HB alone to the other
groups. ∗P < 0.05 vs. 0 mmol/L b-HB.
this study, we found that b-HB (1 mmol/L) increased
medium-released collagen. However, b-HB (1 mmol/L)
failed to induce tubular transdifferentiation. Addition-
ally, TGF-b1 (0.62 ng/mL, the same concentration as
1 mmol/L b-HB–induced TGF-b) also failed to induce
tubular transdifferentiation. Thus, b-HB (1 mmol/L)–
induced TGF-b (0.62 ng/mL) was insufficient to induce
tubular transdifferentiation. However, higher dose of
TGF-b1 (10 ng/mL) did induce tubular transdifferenti-
ation. This observation is similar to a previous study [42].
In this study, we found that b-HB–inhibited mito-
genesis was dependent on TGF-b . Despite the long-
recognized role of TGF-b in diabetic nephropathy [1, 2],
the role of Smads in nondiabetic renal diseases has only
recently been noticed by two studies [43, 44]. One study
found an inverse correlation between Smad7 expression
and the severity of renal fibrosis [43]. The other study
found that Smad7 inhibits the fibrotic effect of TGF-b
on renal tubular epithelial cells by blocking Smad2 ac-
tivation [44]. An overexpression of Smads 2, 3 in dia-
betic nephropathy was also noticed by two recent studies
[7, 8]. In this study, we found that b-HB time dependently
increased nuclear Smad2/3 protein expression at 2 to
8 hours in HK-2 cells.
A specific inhibition of any putative factor in dia-
betic nephropathy is essential to establish the patho-
genetic role of that factor [2]. For example, we have
used the decoy oligodeoxynucleotides to establish the
role of STATs (signal transducers and activators of tran-
scription) in an in vitro model of diabetic nephropathy
[27]. In this study, we showed that transient transfection
of Smad7 and/or dominant-negative Smad3 plasmids re-
versed b-HB–induced growth inhibition, collagen pro-
duction and p21WAF1 and p27kip1 protein expression in
these cells. We also showed that transient transfection
of dominant-negative Smad3 plasmid reversed b-HB–
induced TGF-b transcriptional activity and bioactivity.
This phenomenon of TGF-b autoinduction has also been
found in macrophages by a previous study [45]. Thus,
we have established the causal relationship between the
overexpression of Smad3 and b-HB–induced effects in
these cells.
Diabetic nephropathy is characterized by increased
glucose uptake and gluconeogenesis in the proximal
tubule [46, 47]. Moreover, the mechanism of ketone
body–induced glomerular hyperfiltration has been as-
cribed to enhanced sodium reabsorption accompanied
by ketone body reabsorption by the proximal tubule [36].
2050 Guh et al: TGF-b and Smad3 mediate b-hydroxybutyrate-induced effects in HK-2 cells
There are two mechanisms of b-HB uptake by the proxi-
mal tubule: (1) sodium-dependent, carrier-mediated, and
(2) sodium-independent, carrier-mediated [36]. More-
over, b-HB uptake by the proximal tubule is a saturable
process with a plasma b-HB threshold level of 3 to
5 mmol/L [36].
Filtered ketone bodies are preferentially reabsorbed
and oxidized by the renal tubule under ketotic conditions
as compared to glucose and fatty acids [32, 46]. Oxidative
metabolism of b-HB increases the tissue NADH/NAD+
ratio [31, 47]. In fact, several studies have found that
hyperketonemia increases plasma lipid peroxidation in
vitro [31] and in vivo [48, 49]. Because glucose overutiliza-
tion and oxidative stress are pivotal in causing diabetic
nephropathy [2], we speculate that b-HB oxidation may
account for its biologic effects in HK-2 cells. Indeed, we
found that N-acetylcysteine (an antioxidant) reversed
b-HB–induced Smad 2/3 nuclear translocation and
biologic effects (growth inhibition and collagen
production).
Our findings may have clinical implications because
proximal tubular injury may be the culprit of glomeru-
lar hyperfiltration and tubulointerstitial damage [4, 50].
Additionally, strict glycemic control reduces the inci-
dence of diabetic nephropathy [2]. Because the degree of
ketonemia correlates with the degree of hyperglycemia
[16, 17], strict glycemic control will also reduce ketone-
mia and ketonuria. Thus, ketone body–induced effects in
the proximal tubule will also be reduced.
CONCLUSION
The effects of b-HB on cultured HK-2 cells
includes cell cycle-dependent decrease in cellular
proliferation, enhancement of collagen production,
oxidative stress–dependent activation of Smad 2/3,
increased TGF-b1 mRNA/transcriptional activity, in-
creased TGF-b1 bioactivity, and posttranscriptional
increases in p21WAF1 and p27kip1 protein expression.
Moreover, b-HB–induced growth inhibition was depen-
dent on TGF-b and Smad3 while b-HB–induced-collagen
production and p21WAF1/p27kip1 protein expression were
dependent on Smad3.
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